Company Profile
Jiangxi Fushine Pharmaceutical researches, develops, produces, and sells APIs and pharmaceutical intermediates in China and globally. The company offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates.
Its portfolio also includes argatroban injection for the treatment of acute ischemic stroke, and doxycycline hydrochloride dispersible tablets to treat rickettsial diseases, mycoplasmal and chlamydial infections, relapsing fever, brucellosis, cholera, tularemia, plague, and chancroid
Lithium-ion battery electrolyte additives; and microbial protein, amino acid water-soluble fertilizer, and bio-fermentation products. Founded in 2002 and headquartered in Jingdezhen, China, Jiangxi Fushine Pharmaceutical was formerly known as Jingdezhen Fuxiang Pharmaceutical Co., Ltd before rebranding in August 2012.